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Introduction {#sec005}
============

*Staphylococcus aureus*, one of the major nosocomial and community-acquired pathogens, causes a variety of clinical problems, including infections of the skin and soft tissues \[[@pone.0136082.ref001]\]. Since the 1960s, the prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) has increased at a dramatic rate \[[@pone.0136082.ref002], [@pone.0136082.ref003]\], and is associated with higher rates of morbidity and mortality than methicillin-susceptible *S*. *aureus* (MSSA) \[[@pone.0136082.ref004]\].

Glycopeptides, such as vancomycin, are popular and effective antimicrobial drugs for treating MRSA. Unfortunately, vancomycin-intermediate *S*. *aureus* (VISA) and heterogeneous VISA (hVISA) have been reported since 1997. hVISA is an *S*. *aureus* isolate with a minimum inhibitory concentration (MIC) for vancomycin within the susceptible range when tested with routine methods, but in which a proportion of the cell population is within the vancomycin-intermediate range \[[@pone.0136082.ref005]\]. hVISA/VISA infections are commonly associated with persistent infections, prolonged bacteremia, and/or prolonged hospitalization \[[@pone.0136082.ref006]--[@pone.0136082.ref009]\]. Today, there is growing concern that hVISA and VISA are becoming prevalent worldwide \[[@pone.0136082.ref010]--[@pone.0136082.ref012]\].

In recent years, there have been many reports from single medical centers or individual countries of the incidence of hVISA/VISA, but few systematic reviews or meta-analyses on their prevalence. The review by Liu et al. on the epidemiology of hVISA/VISA was published over 10 years ago \[[@pone.0136082.ref013]\]. Another meta-analysis, by Van Hal et al., selectively analyzed the clinical significance and outcomes of hVISA \[[@pone.0136082.ref009]\]. In this systematic review and meta-analysis, we pooled the published studies that have reported the prevalence of hVISA/VISA, and made subgroup comparisons of the incidence of hVISA/VISA in different years, locations, and types of clinical samples. We also analyzed the genetic backgrounds of these strains. The results of this study will help to clarify the epidemiology of hVISA/VISA and will advance the control and management of these drug-resistant isolates.

Methods {#sec006}
=======

Search strategy {#sec007}
---------------

Two independent examiners (S.S.Z. and X.X.S.) performed a systematic literature review of potentially relevant studies pertaining to VISA and hVISA. The studies were identified in the PubMed and EMBASE databases from articles published between January 1997 and August 2014. The following terms and connectors were used in the search strategy: (1) 'vancomycin-intermediate *Staphylococcus aureus*', VISA; (2) 'heterogeneous vancomycin-intermediate *Staphylococcus aureus*', hVISA; (3) '*Staphylococcus aureus* with reduced vancomycin susceptibility', SA-RVS; (4) 'glycopeptide-intermediate *Staphylococcus aureus*', GISA; and (5) 'heterogeneous glycopeptide-intermediate *Staphylococcus aureus*', hGISA. The search was restricted to human studies.

Selection of studies {#sec008}
--------------------

Studies identified in the literature search were checked by title and abstract. The papers with relevant abstracts were examined in full. The criteria for the inclusion and exclusion of the studies were established by the investigators before the literature was reviewed. The inclusion criteria were as follows: (1) studies that were original articles, short communications, correspondence, or letters that provided sufficient original data about the prevalence of hVISA/VISA; (2) studies in which all MRSA strains were randomly selected; (3) studies that used normative and publicly accepted detection methods for hVISA/VISA; and (4) studies that were published in English. The exclusion criteria were: (1) studies that contained duplicate data or were overlapping articles; (2) reviews and conference abstracts; and (3) articles that included fewer than 10 cases.

Data extraction {#sec009}
---------------

Two authors independently ascertained the characteristics of each study, including the first author's surname, year of publication, continent, country, study years, isolate source, detection method, hVISA frequency, VISA frequency, and genotypes. When there was disagreement, the relevant paper was reviewed and the differences were resolved by consensus.

Assessment of study quality {#sec010}
---------------------------

The studies were assessed for quality, and only high-quality studies were included in the analysis. The criteria for high-quality studies were (1) that they provided basic data that included the study period and area, total number of isolates tested, and number of hVISA/VISA isolated; and (2) that they used dilution methods or E-test to detect VISA, and population analysis profile--area under the curve (PAP-AUC), macromethod Etest (MET), or screening agar to detect hVISA. When two studies overlapped, the more recent and larger study was included in the analysis. If one article included more than one study period, it was divided into several independent studies.

Statistical analysis {#sec011}
--------------------

Statistical analyses were performed with STATA version 12.0. The data were pooled using the fixed-effects model (FEM) \[[@pone.0136082.ref014]\] and the random-effects model (REM) \[[@pone.0136082.ref015]\]. Statistical heterogeneity was assessed using the Cochran Q and I^2^ statistical methods \[[@pone.0136082.ref016]\]. P \< 0.1 was considered statistically significant. For all analyses, the results of FEM are presented only when there was no heterogeneity between the studies. Otherwise, the results of REM are presented. Freeman--Tukey arcsine transformations were performed to stabilize the variances, and after the meta-analysis, we transformed the summary estimates and the confidence interval (CI) boundaries back to proportions using the sine function \[[@pone.0136082.ref017]\].

Results {#sec012}
=======

Results of the systematic literature search {#sec013}
-------------------------------------------

In total, 1258 citations were identified in the initial electronic database search. Ultimately, 91 studies were included, based on the inclusion and exclusion criteria ([Fig 1](#pone.0136082.g001){ref-type="fig"}). These 91 studies that reported the prevalence of hVISA/VISA included 39 from Asia, 28 from Europe, 21 from America, and 3 from Australia ([Table 1](#pone.0136082.t001){ref-type="table"}) \[[@pone.0136082.ref018]--[@pone.0136082.ref108]\]. In the pooled analysis, hVISA was reported in 76 studies, with an overall prevalence of 6.05% among 99,042 MRSA strains (95% CI 4.78--7.48), and VISA was reported in 38 studies, with a prevalence of 3.01% among 68,792 MRSA strains (95% CI 1.62--4.83) ([Table 2](#pone.0136082.t002){ref-type="table"}).

![Flowchart of study selection.](pone.0136082.g001){#pone.0136082.g001}
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###### Characteristics of the eligible studies.

![](pone.0136082.t001){#pone.0136082.t001g}

  Study, Year Published                                  Country, Continent    Study Year              Isolate Source         Detection Method[^a^](#t001fn001){ref-type="table-fn"}   hVISA Frequency (%) and Genotype (%)   VISA Frequency (%) and Genotype (%)
  ------------------------------------------------------ --------------------- ----------------------- ---------------------- -------------------------------------------------------- -------------------------------------- -------------------------------------
  Hanaki et al, 2007\[[@pone.0136082.ref076]\]           Japan, Asia           1978--2005              All clinical samples   E-test                                                                                          5/2446
                                                                                                                                                                                                                              (0.2)5/5 (100) SCC*mec* II
  Hiramatsu et al, 1997\[[@pone.0136082.ref036]\]        Japan, Asia           1996/01--1997/03        All clinical samples   BHI                                                      34/1149 (3.0)                          
  Song et al, 2004\[[@pone.0136082.ref038]\]             Asia                  1997/01--2000/03        All clinical samples   BHI                                                      58/1357 (4.3)                          
                                                                                                                              PAP                                                                                             
  Wong et al, 1999\[[@pone.0136082.ref020]\]             Hong Kong, Asia       1997/07--1998/06        All clinical samples   E-test                                                   3/52 (5.8)                             
  Ike et al, 2001\[[@pone.0136082.ref075]\]              Japan, Asia           1997/09--1997/12        All clinical samples   BHI                                                      0/6625 (0)                             
                                                                                                                              PAP                                                                                             
  Trakulsomboon et al, 2001\[[@pone.0136082.ref045]\]    Thailand, Asia        1998--1999              All clinical samples   BHI                                                      5/155 (3.2)                            
                                                                                                                              PAP                                                                                             
  Neoh et al, 2007\[[@pone.0136082.ref056]\]             Japan, Asia           1998/01--2005/10        Blood samples          PAP-AUC                                                  2/20 (10.0)                            
  Kim et al, 2002\[[@pone.0136082.ref027]\]              Korea, Asia           1998/12--1999/08        All clinical samples   BHI                                                      24/3363 (0.7)                          0/3363 (0)
                                                                                                                              PAP                                                                                             
  Aminaka et al, 2009\[[@pone.0136082.ref034]\]          Japan, Asia           1999                    All clinical samples   BHI                                                      7/138 (5.1)                            0/138 (0)
                                                                                                                              PAP                                                                                             
  Kim et al, 2000\[[@pone.0136082.ref108]\]              Korea,Asia            1999/01--1999/08        All clinical samples   PAP                                                      59/3371 (1.8)                          
  Kim et al, 2003\[[@pone.0136082.ref073]\]              Korea, Asia           1999/06--2001/01        All clinical samples   BHI                                                      0/439 (0)                              
                                                                                                                              PAP                                                                                             
  Hsueh et al, 2010\[[@pone.0136082.ref026]\]            Taiwan, Asia          2001/09--2002/08        All clinical samples   MIC based                                                                                       43/1500
                                                                                                                                                                                                                              (2.9) 43/43 (100) SCC*mec* III
  Wang et al, 2009\[[@pone.0136082.ref070]\]             Taiwan, Asia          2001--2003              All clinical samples   BHI                                                      2/13 (15.3)                            8/13 (61.5)
                                                                                                                              PAP                                                      1/2 (50.0) SCC*mec* IV-ST59            5/8 (62.5) SCCmec IV-ST59
                                                                                                                                                                                       1/2 (50.0) SCC*mec* III-ST239          3/8 (37.5) SCCmec III-ST239
  Ghung et al, 2010\[[@pone.0136082.ref074]\]            Korea, Asia           2001--2006              All clinical samples   MIC based                                                18/41639 (0.04)                        15/41639 (0.04)
                                                                                                                              PAP-AUC                                                  12/18 (66.7) SCC*mec* II-ST5           12/15(80.0) SCC*mec* III-ST239
                                                                                                                                                                                       4/18 (22.2) SCC*mec* IV-ST72           2/15 (13.3) SCC*mec* II-ST5
                                                                                                                                                                                       1/18 (5.6) SCC*mec* III-ST239          1/15 (6.7) SCC*mec* IV-ST72
                                                                                                                                                                                       1/18 (5.6) SCC*mec* IV-ST1             
  Lulitanond et al, 2009\[[@pone.0136082.ref046]\]       Thailand, Asia        2002/08--2003/04        All clinical samples   BHI                                                      4/533 (0.8)                            
                                                                                                                              PAP                                                      4/4 (100) SCC*mec* III-ST239           
  Maor et al, 2009\[[@pone.0136082.ref025]\]             Israel, Asia          2003--2006              Blood samples          MET                                                      27/223 (12.1)                          
  Maor et al, 2007\[[@pone.0136082.ref082]\]             Israel, Asia          2003/01--2004/12        Blood samples          MET                                                      16/264 (6.0)                           
  Ho et al, 2010\[[@pone.0136082.ref081]\]               Taiwan, Asia          2003/03--2003/08        All clinical samples   BHI                                                      7/1000 (0.7)                           2/1000 (0.2)
                                                                                                                              PAP-AUC                                                                                         
  Aminaka et al, 2009\[[@pone.0136082.ref034]\]          Japan, Asia           2005--2006              All clinical samples   BHI                                                      3/477 (0.6)                            0/477 (0)
                                                                                                                              PAP                                                                                             
  Sun et al, 2009\[[@pone.0136082.ref083]\]              China, Asia           2005--2007              Blood samples          MET                                                      26/200 (13.1)                          1/200 (0.5)
                                                                                                                              PAP-AUC                                                  20/26(77.0) SCC*mec* III-ST239         1/1 (100) SCC*mec* II-ST5
                                                                                                                                                                                       5/26 (19.2) SCC*mec* II-ST5            
                                                                                                                                                                                       1/26 (3.8) SCC*mec* IV-ST59            
  Campanile et al, 2010\[[@pone.0136082.ref052]\]        India, Asia           2005--2007              All clinical samples   BHI, MET                                                 36/139 (25.9)                          0/139 (0)
                                                                                                                              PAP-AUC                                                  3/36 (8.3) ST8                         
                                                                                                                                                                                       3/36 (8.3) ST239                       
                                                                                                                                                                                       15/36 (41.7) ST247                     
                                                                                                                                                                                       12/36 (33.3) ST228                     
                                                                                                                                                                                       3/36 (8.3) others                      
  Chen et al, 2011\[[@pone.0136082.ref058]\]             China, Asia           2005--2008              All clinical samples   PAP-AUC                                                  62/559 (11.1)                          0/559 (0)
  Fong et al, 2009\[[@pone.0136082.ref023]\]             Singapore, Asia       2005/01--2006/12        Blood samples          MET                                                      3/56 (5.4)                             
  Wang et al, 2013\[[@pone.0136082.ref055]\]             Taiwan, Asia          2005/01--2009/12        Blood samples          E-test GRD                                               16/284 (5.6)                           
                                                                                                                              PAP-AUC                                                  7/16 (43.8) ST239                      
                                                                                                                                                                                       5/16 (31.4) ST5                        
                                                                                                                                                                                       1/16 (6.2) ST59, ST45, ST398, ST900    
  El Ayoubi et al, 2014\[[@pone.0136082.ref048]\]        Lebanon, Asia         2006/02--2013/03        All clinical samples   MIC based                                                                                       5/113 (3.8)
  Lulitanond et al, 2009\[[@pone.0136082.ref046]\]       Thailand, Asia        2006/09--2007/12        All clinical samples   BHI                                                      8/361 (2.2)                            3/361 (0.8)
                                                                                                                              PAP                                                      8/8 (100) SCC*mec* III-ST239           2/3 (66.7) SCC*mec* III-ST239
                                                                                                                                                                                                                              1/3 (33.3) SCC*mec* II-ST5
  Wang et al, 2013\[[@pone.0136082.ref084]\]             China, Asia           2007/07-2009/03         All clinical samples   MET                                                      25/122 (20.5)                          
                                                                                                                                                                                       23/25 (92.0) SCC*mec* III              
                                                                                                                                                                                       2/25 (8.0) SCC*mec* II                 
  Hanaki et al, 2014\[[@pone.0136082.ref019]\]           Japan, Asia           2008/01--2011/05        Blood samples          MET                                                      55/830 (6.5)                           8/830 (1.0)
                                                                                                                              PAP-AUC                                                                                         
  Park et al, 2012\[[@pone.0136082.ref028]\]             Korea,Asia            2008/08--2010/09        Blood samples          E-test                                                   101/268 (37.7)                         
                                                                                                                              PAP-AUC                                                  73/268 (72.3) SCC*mec* II-ST5          
                                                                                                                                                                                       17/268(16.8) SCC*mec* IV-ST72          
                                                                                                                                                                                       9/268 (8.9) SCC*mec* III-ST239         
                                                                                                                                                                                       2/268 (3.0) others                     
  Gowrishankar et al, 2013\[[@pone.0136082.ref040]\]     India, Asia           2009--2010              All clinical samples   MHA                                                                                             10/63 (15.9)
  Norazah et al, 2012\[[@pone.0136082.ref079]\]          Malaysia, Asia        2009/01--2009/12        All clinical samples   E-test GRD                                               2/43 (4.7)                             
                                                                                                                              PAP-AUC                                                                                         
  Ramli et al, 2012\[[@pone.0136082.ref094]\]            Malaysia, Asia        2009/02--2009/05        All clinical samples   E-test GRD                                               7/320 (2.2)                            
                                                                                                                              PAP-AUC                                                                                         
  Lin et al, 2012\[[@pone.0136082.ref072]\]              Taiwan, Asia          2009/03--2009/12        Blood samples          MET                                                      5/62 (8.1)                             
                                                                                                                              PAP-AUC                                                  3/5 (60.0) SCC*mec* III-ST239          
                                                                                                                                                                                       1/5 (20.0) SCC*mec* III-ST900          
                                                                                                                                                                                       1/5 (20.0) SCC*mec* II-ST5             
  Dubey et al, 2013\[[@pone.0136082.ref099]\]            India, Asia           2009/09--2012/04        All clinical samples   E-test                                                                                          545/1214 (44.9)
  Khanal et al, 2010\[[@pone.0136082.ref087]\]           Nepal, Asia           2010                    All clinical sample    Arg screening                                                                                   80/300 (26.6)
  Chaudhari et al, 2015\[[@pone.0136082.ref051]\]        India, Asia           2010/09--2013/03        All clinical samples   BHI                                                      4/58 (6.9)                             
                                                                                                                              PAP-AUC                                                                                         
  Panomket et al, 2014\[[@pone.0136082.ref068]\]         Thailand, Asia        2010/11--2011/11        All clinical samples   BHI                                                      2/68 (2.9)                             
                                                                                                                              PAP-AUC                                                                                         
  Liu et al, 2014\[[@pone.0136082.ref071]\]              China, Asia           2011/06--2012/05        All clinical samples   PAP-AUC                                                  17/77 (22.1)                           
                                                                                                                                                                                       15/17(88.2) SCC*mec* III-ST239         
                                                                                                                                                                                       1/17 (5.9) SCC*mec* III-ST5            
                                                                                                                                                                                       1/17 (5.9) SCC*mec* II-ST1301          
  Kaleem et al, 2012\[[@pone.0136082.ref031]\]           Pakistan, Asia        2012                    All clinical samples   E-test                                                   6/347 (1.7)                            
  Guo et al, 2013\[[@pone.0136082.ref100]\]              China, Asia           2012/06--2012/12        All clinical sample    MIC based                                                                                       1/1790 (0.06)
  Chaudhary et al, 2013\[[@pone.0136082.ref085]\]        India, Asia           2013                    All clinical samples   MHA                                                      8/130 (6.1)                            
                                                                                                                              E-test                                                                                          
  Wootton et al, 2001\[[@pone.0136082.ref069]\]          UK, Europe            1983--1999              All clinical sample    E-test                                                   0/100 (0)                              
                                                                                                                              PAP-AUC                                                                                         
  Robert et al, 2006\[[@pone.0136082.ref032]\]           France, Europe        1983--2001              All clinical samples   E-test                                                                                          1/1445 (0.07)
  Geisel et al, 1999\[[@pone.0136082.ref039]\]           Germany, Europe       1992--1998              All clinical samples   BHI                                                      7/85 (8.2)                             
  Kantzanou et al,1999\[[@pone.0136082.ref091]\]         Greece, Europe        1994--1997              All clinical samples   E-test                                                   1/72 (1.5)                             
                                                                                                                              PAP                                                                                             
  Uçkay et al, 2012\[[@pone.0136082.ref054]\]            Switzerland, Europe   1995/01--2003/08        All clinical samples   BHI                                                                                             55/208 (26.4)
  Bierbaum et al, 1999\[[@pone.0136082.ref080]\]         Germany, Europe       1997                    All clinical samples   BHI                                                      2/367 (0.5)                            
                                                                                                                              PAP                                                                                             
  Bert et al, 2003\[[@pone.0136082.ref088]\]             France, Europe        1997/01--2002/01        All clinical samples   MET                                                      13/48 (27.1)                           
                                                                                                                              PAP                                                                                             
  Schmitz et al, 1999\[[@pone.0136082.ref101]\]          Europe                1997/04--1998/04        All clinical samples   E-test                                                   0/302 (0)                              
  Marchese et al, 2000\[[@pone.0136082.ref050]\]         Italy, Europe         1997/08--1998/12        All clinical samples   BHI                                                      2/179 (1.1)                            
                                                                                                                              PAP                                                                                             
  Canton et al, 1999\[[@pone.0136082.ref090]\]           Spain, Europe         1997/10--1998/01        All clinical samples   E-test                                                                                          12/248 (4.8)
  Fitzgibbon et al, 2007\[[@pone.0136082.ref060]\]       Ireland, Europe       1998--2004              All clinical samples   MET                                                      73/3189 (2.3)                          
                                                                                                                              PAP-AUC                                                                                         
  Sancak et al, 2005\[[@pone.0136082.ref067]\]           Turkey, Europe        1998/01--2002/01        All clinical samples   MET                                                      46/256 (18.0)                          0/256 (0)
                                                                                                                              PAP                                                                                             
  Aucken et al, 2000\[[@pone.0136082.ref102]\]           UK, Europe            1998/05--1999/04        All clinical samples   MIC                                                      0/11242 (0)                            
                                                                                                                              BHI                                                                                             
  Reverdy et al, 2001\[[@pone.0136082.ref059]\]          French, Europe        1998/11--1999/04        All clinical samples   MET                                                      5/171 (2.9)                            
                                                                                                                              PAP                                                                                             
  Lassence et al, 2006\[[@pone.0136082.ref030]\]         France, Europe        1999--2000              All clinical samples   MHA                                                      11/329 (3.3)                           
                                                                                                                              E-test                                                                                          
  Denis et al, 2002\[[@pone.0136082.ref041]\]            Belgium, Europe       1999/01--1999/12        Blood samples          BHI                                                      4/2145 (0.1)                           3/2145 (0.1)
                                                                                                                              PAP                                                                                             
  Vaudaux et al, 2012\[[@pone.0136082.ref086]\]          Switzerland, Europe   2000--2008              All clinical samples   MHA                                                                                             13/57 (31.7)
                                                                                                                                                                                                                              13/13 (100) SCC*mec* I-ST228
  Nonhoff et al, 2005\[[@pone.0136082.ref065]\]          Belgium, Europe       2001/01--2001/12        All clinical samples   E-test                                                   3/455 (0.7)                            
                                                                                                                                                                                       2/3 (66.7) SCC*mec* I                  
                                                                                                                                                                                       1/3 (33.3) SCC*mec* IV                 
  Cartolano et al, 2004\[[@pone.0136082.ref066]\]        France, Europe        2000/06                 All clinical samples   MHA                                                                                             31/1070 (2.9)
                                                                                                                              PAP-AUC                                                                                         
  Garnier et al, 2006\[[@pone.0136082.ref018]\]          France, Europe        2001/07--2002/06        All clinical samples   MET                                                      255/2300 (11.1)                        
                                                                                                                              PAP-AUC                                                                                         
  Nakipoglu et al, 2005\[[@pone.0136082.ref061]\]        Turkey, Europe        2001/09--2002/04        All clinical samples   BHI                                                      7/135 (5.1)                            
                                                                                                                              PAP                                                                                             
  Mlynarczyk et al, 2003\[[@pone.0136082.ref096]\]       Poland, Europe        2002                    All clinical samples   PAP-AUC                                                  5/103 (4.8)                            0/103 (0)
  Bataineh et al, 2006\[[@pone.0136082.ref093]\]         Spain, Europe         2002/04--2004/08        All clinical samples   MHA                                                      5/139 (3.6)                            
                                                                                                                              E-test                                                                                          
  Piérard et al, 2004\[[@pone.0136082.ref095]\]          Belgium, Europe       2003                    All clinical samples   MET                                                      5/1002 (0.5)                           1/1002 (0.1)
                                                                                                                              PAP                                                                                             
  Kirby et al, 2010\[[@pone.0136082.ref098]\]            UK, Europe            2004--2006              All clinical samples   MET                                                      86/2550 (3.4)                          
                                                                                                                              PAP-AUC                                                                                         
  Lewis et al, 2009\[[@pone.0136082.ref043]\]            UK, Europe            2005--2007              Blood samples          MET                                                      35/195 (18.0)                          
                                                                                                                                                                                       35/35 (100) SCC*mec* IV                
  Parer et al, 2012\[[@pone.0136082.ref078]\]            France, Europe        2007                    All clinical samples   MHA                                                      12/20 (60.0)                           
                                                                                                                              PAP-AUC                                                                                         
  Sancak et al, 2013\[[@pone.0136082.ref103]\]           Turkey, Europe        2009--2010              Blood samples          MET                                                      24/175 (13.7)                          0/175 (0)
                                                                                                                              PAP-AUC                                                                                         
  Rybak et al, 2008\[[@pone.0136082.ref021]\]            USA, America          1986--1993              All clinical samples   MET                                                      5/225 (2.2)                            1/225 (0.4)
                                                                                                                              PAP-AUC                                                  3/5 (56.9) SCC*mec* II                 
                                                                                                                                                                                       2/5 (38.4) SCC*mec* IV                 
  Ariza et al, 1999\[[@pone.0136082.ref104]\]            USA, America          1990/01--1997/12        All clinical samples   E-test                                                   14/19 (73.7)                           
                                                                                                                              PAP                                                                                             
  Rybak et al, 2008\[[@pone.0136082.ref021]\]            USA, America          1994--2002              All clinical samples   MET                                                      27/356 (7.6)                           8/356 (2.3)
                                                                                                                              PAP-AUC                                                  15/27 (56.9) SCC*mec* II               
                                                                                                                                                                                       10/27 (38.4) SCC*mec* IV               
                                                                                                                                                                                       2/27 (4.7) others                      
  Adam et al, 2010\[[@pone.0136082.ref033]\]             Canada, America       1995--2006              All clinical samples   E-test GRD                                               25/475 (5.3)                           
                                                                                                                              PAP-AUC                                                  16/25 (64.0) SCC*mec* II               
                                                                                                                                                                                       6/25 (24.0) SCC*mec* I                 
                                                                                                                                                                                       2/25 (8.0) SCC*mec* III                
                                                                                                                                                                                       1/25 (4.0) SCC*mec* IV                 
  Musta et al, 2009\[[@pone.0136082.ref105]\]            USA, America          1996--1997              Blood samples          MHA                                                      8/61 (13.1)                            
                                                                                                                              E-test                                                   7/8 (93.0) SCC*mec* II                 
                                                                                                                                                                                       1/8 (7.0) SCC*mec* IV                  
  Hubert et al, 1999\[[@pone.0136082.ref049]\]           USA, America          1997                    All clinical samples   MHA                                                                                             4/630 (0.6)
                                                                                                                              PAP-AUC                                                                                         
  Tallent et al, 2002\[[@pone.0136082.ref106]\]          USA, America          1997/01--2000/12        Blood samples          MIC based                                                1/619 (0.2)                            
                                                                                                                              PAP                                                                                             
  Franchi et al, 1999\[[@pone.0136082.ref097]\]          USA, America          1997/03--1997/05        All clinical samples   E-test PAP                                                                                      0/30 (0)
  Fridkin et al, 2003\[[@pone.0136082.ref042]\]          USA, America          1999/03--2000/12        All clinical samples   BHI                                                                                             6/102 (5.8)
  Eguia et al, 2005\[[@pone.0136082.ref063]\]            USA, America          1999/12--2000/08        All clinical samples   BHI                                                      0/211 (0)                              
  Musta et al, 2009\[[@pone.0136082.ref105]\]            USA, America          2000--2001              Blood samples          MHA                                                      5/55 (9.1)                             
                                                                                                                              E-test                                                   5/5 (100) SCC*mec* II                  
  Pitz et al,2011\[[@pone.0136082.ref107]\]              USA, America          2000--2008              Blood samples          E-test GRD                                               2/167 (1.2)                            
                                                                                                                              PAP-AUC                                                                                         
  Musta et al, 2009\[[@pone.0136082.ref105]\]            USA, America          2002--2003              Blood samples          MHA                                                      37/187 (19.8)                          
                                                                                                                              E-test                                                   34/37 (93.0) SCC*mec* II               
                                                                                                                                                                                       3/37 (7.0) SCC*mec* IV                 
  Sader et al, 2009\[[@pone.0136082.ref077]\]            USA, America          2002--2006              Blood samples          MET                                                      36/268 (13.4)                          
                                                                                                                              PAP-AUC                                                                                         
  Pastagia et al, 2009\[[@pone.0136082.ref022]\]         USA, America          2002--2007              Blood samples          E-test                                                   45/699 (6.4)                           118/699 (16.9)
  Khosrovaneh et al, 2004\[[@pone.0136082.ref047]\]      USA, America          2002/01--2002/12        Blood samples          BHI                                                      3/22 (13.6)                            
                                                                                                                              PAP-AUC                                                                                         
  Casapao et al, 2014\[[@pone.0136082.ref044]\]          USA, America          2002/01--2013/06        All clinical samples   PAP-AUC                                                  38/266 (18.8)                          
                                                                                                                                                                                       26/38 (68.4) SCC*mec* IV               
                                                                                                                                                                                       11/38 (28.9) SCC*mec* II               
                                                                                                                                                                                       1/38 (2.7) SCC*mec* III                
  Khatib et al, 2011\[[@pone.0136082.ref092]\]           USA, America          2002--03 and 2005--06   Blood samples          MET                                                      30/371 (8.1)                           6/371 (1.6)
                                                                                                                              PAP-AUC                                                  26/30 (86.7) SCC*mec* II               6/6 (100) SCC*mec* II
                                                                                                                                                                                       4/30 (13.3) others                     
  Rybak et al, 2008\[[@pone.0136082.ref021]\]            USA, America          2003--2007              All clinical samples   MET                                                      76/917 (8.3)                           3/917 (0.3)
                                                                                                                              PAP-AUC                                                  43/76 (56.9) SCC*mec* II               
                                                                                                                                                                                       29/76 (38.4) SCC*mec* IV               
                                                                                                                                                                                       4/76 (4.7) others                      
  Delgado et al, 2007\[[@pone.0136082.ref053]\]          Mexico, America       2003/09--2004/08        All clinical samples   PAP                                                      1/152 (0.7)                            
  Musta et al, 2009\[[@pone.0136082.ref105]\]            USA, America          2005--2006              Blood samples          MHA                                                      21/186 (11.3)                          
                                                                                                                              E-test                                                   20/21 (93.0) SCC*mec* II               
                                                                                                                                                                                       1/21 (7.0) SCC*mec* IV                 
  Kosowska-Shick et al, 2008\[[@pone.0136082.ref057]\]   USA, America          2006/08--2007/12        All clinical samples   MET                                                      2/982 (0.2)                            3/982 (0.3)
                                                                                                                              PAP                                                                                             2/3 (66.7) SCC*mec* II
                                                                                                                                                                                                                              1/3 (33.3) SCC*mec* IV
  Hafer et al, 2012\[[@pone.0136082.ref029]\]            USA, America          2007--2008              All clinical samples   MIC based                                                9/77 (11.7)                            22/77 (28.6)
                                                                                                                              PAP-AUC                                                                                         11/22 (50.0) ST5
                                                                                                                                                                                                                              11/22 (50.0) ST8
  Fink et al, 2012\[[@pone.0136082.ref064]\]             USA, America          2008/02--2010/01        All clinical samples   E-test GRD                                               0/288 (0)                              
                                                                                                                              PAP-AUC                                                                                         
  Richter et al, 2011\[[@pone.0136082.ref035]\]          USA, America          2009/06--2009/12        All clinical samples   E-test GRD                                               11/4210 (0.4)                          0/4210 (0)
                                                                                                                              PAP-AUC                                                                                         
  Silveira et al, 2014\[[@pone.0136082.ref062]\]         Brazil, America       2009/03--2013/02        All clinical samples   E-test GRD                                               12/124 (9.7)                           
                                                                                                                              PAP-AUC                                                                                         
  Van Hal et al, 2011\[[@pone.0136082.ref037]\]          Australia, Oceania    1997--2008              Blood samples          PAP-AUC                                                  54/465 (11.6)54/54 (100) ST239         
  Charles et al, 2004\[[@pone.0136082.ref024]\]          Australia, Oceania    2001/07--2002/06        Blood samples          E-test                                                   5/53 (9.4)                             0/53 (0)
                                                                                                                              PAP-AUC                                                                                         
  Horne et al, 2009\[[@pone.0136082.ref089]\]            Australia, Oceania    2005/03--2005/12        All clinical samples   MIC based                                                56/117 (47.9)                          2/117 (1.7)
                                                                                                                              PAP-AUC                                                                                         

^a^ BHI: Brain Heart Infusion Agar; PAP: Population Analysis Profile; PAP-AUC: Population Analysis Profile--Area Under the Curve; MET: Macromethod E-test; MHA: Muller Hinton Agar; E-test GRD: E-test Glycopeptide Resistant Detection

10.1371/journal.pone.0136082.t002

###### Prevalence of hVISA and VISA based on study period, origin of study, and isolate selection.[^a^](#t002fn002){ref-type="table-fn"}

![](pone.0136082.t002){#pone.0136082.t002g}

          Category          Subcategory             No. Studies   No. Strains   Prevalence (%) (95% CI)
  ------- ----------------- ----------------------- ------------- ------------- -------------------------
  hVISA   Overall                                   76            99042         6.05 (4.78--7.48)
          Study period      Before 2006             42            40119         4.68 (3.19--6.41)
                            2006--2009              10            6485          5.38 (2.40--9.48)
                            2010--2014              5             680           7.01 (2.12--14.42)
          Continent         Asia                    35            64692         6.81 (4.76--9.16)
                            Europe-America          41            34350         5.60 (3.85--7.64)
          Clinical sample   Blood culture sample    21            5944          9.81 (6.71--13.42)
                            All clinical sample     55            93098         4.68 (3.51--6.00)
  VISA    Overall                                   38            68792         3.01 (1.62--4.83)
          Study period      Before 2006             20            13394         2.05 (0.95--3.55)
                            2006--2009              4             5630          2.63 (0.29--7.22)
                            2010--2014              2             2090          7.93 (0.06--26.67)
          Continent         Asia                    18            55362         3.42 (1.10--6.99)
                            Europe-America          20            13430         2.75 (1.19--4.91)
          Clinical sample   Blood culture samples   7             2542          2.00 (0.03--6.88)
                            All clinical samples    31            66250         3.24 (1.67--5.29)

CI, confidence interval

^a^ References: \[[@pone.0136082.ref018]--[@pone.0136082.ref108]\].

Prevalence of hVISA/VISA in different study periods {#sec014}
---------------------------------------------------

To analyze the trends in the changes in hVISA/VISA prevalence in recent years, we performed a subgroup analysis of the prevalence of these two types of strains according to the study year. Three periods (before 2006, 2006--2009, and 2010--2014) were designated. Some studies that did not conform to the periods (e.g., reported for 2003--2007) were not included in this analysis.

It can be seen from [Table 2](#pone.0136082.t002){ref-type="table"} that the prevalence of the hVISA isolates increased gradually from 4.68% (95% CI 3.19--6.41) of 40,119 MRSA strains before 2006 to 5.38% (95% CI 2.40--9.48) of 6485 strains in 2006--2009, reaching 7.01% (95% CI 2.12--14.42) of 680 strains in 2010--2014. The incidence of VISA was 2.05% (95% CI 0.95--3.55) of 13,394 strains before 2006, 2.63% (95% CI 0.29--7.22) of 5,630 strains in 2006--2009, and 7.93% (95% CI 0.06--26.67) of 2090 strains in 2010--2014. Thus, the frequency of VISA during the years 2010--2014 represents a 3.87-fold increase over the years before 2006.

Prevalence of hVISA/VISA at different locations {#sec015}
-----------------------------------------------

The prevalence of hVISA/VISA differed among geographic regions in the subgroup analysis, as shown in [Table 2](#pone.0136082.t002){ref-type="table"}. The prevalence of hVISA was 6.81% (95% CI 4.76--9.16) of 64,692 MRSA strains in 35 studies from Asia, and 5.60% (95% CI 3.85--7.64) of 34,350 strains in 41 studies from Europe/America. Moreover, 3.42% (95% CI 1.10--6.99) of 55,362 MRSA strains were VISA in 18 studies from Asia compared with 2.75% (95% CI 1.19--4.91) of 13,430 strains in 20 studies from Europe/America.

Prevalence of hVISA/VISA in different clinical samples {#sec016}
------------------------------------------------------

In this subgroup analysis, we divided the MRSA strains into two groups. One group was isolated from only blood culture samples and the other from all clinical samples, including blood, sputum, pus, urine, and so forth (the authors of the original studies did not classify the prevalence rates in the different types of samples). In total, the frequency of hVISA was 9.81% (95% CI 6.71--13.42) in 5944 MRSA strains isolated from blood culture samples reported in 21 studies, significantly higher than in the group of all clinical samples (4.68% \[95% CI 3.51--6.00\] in 93,098 strains in 55 studies) (P = 0.023). The prevalence rates for VISA were 2.00% (95% CI 0.03--6.88) in 2542 blood-borne MRSA strains in seven studies, and 3.07% (95% CI 1.58--5.02) in 66,250 strains isolated from all clinical samples in another 32 studies ([Table 2](#pone.0136082.t002){ref-type="table"}).

Genetic backgrounds of hVISA/VISA {#sec017}
---------------------------------

As shown in [Table 3](#pone.0136082.t003){ref-type="table"}, 25 studies presented information on the genotypes of the hVISA/VISA strains. Sixteen studies that included 685 MRSA strains reported the staphylococcal cassette chromosome *mec* (SCC*mec*) types for hVISA. The predominant type was SCC*mec* II, which accounted for 48.16% of hVISA (95% CI 32.82--63.68), followed by SCC*mec* IV (18.07%; 95% CI 7.50--31.98) and SCC*mec* III (17.99%; 95% CI 7.69--31.42). SCC*mec* I accounted for only 2.12% (95% CI 0.70--4.30). Among the 454 strains from 10 studies that reported multilocus sequence typing (MLST), 11 ST types were identified. ST239 was found in 58.62% (95% CI 22.98--89.73) of hVISA, followed by ST5 in 14.45% (95% CI 4.59--28.53) and ST72 in 3.28% (95% CI 0.98--6.88). The SCC*mec* types in VISA strains were reported in nine studies, which included 97 strains. SCC*mec* II was predominant (37.74%, 95% CI 10.01--70.94), followed by SCC*mec* III (32.72%, 95% CI 3.35--73.85). SCC*mec* I and SCC*mec* IV accounted for 11.79% (95% CI 0.01--40.76) and 10.08% (95% CI 1.77--24.05) of isolates, respectively. Six ST types were reported among the VISA strains in 62 strains in six studies. The most prevalent ST types were ST239 (27.05%, 95% CI 2.34--65.22) and ST5 (22.77%, 95% CI 4.66--49.26) ([Table 3](#pone.0136082.t003){ref-type="table"}).

10.1371/journal.pone.0136082.t003

###### Genetic prevalence of hVISA and VISA.[^a^](#t003fn002){ref-type="table-fn"}

![](pone.0136082.t003){#pone.0136082.t003g}

          Category   Subcategory                                       No. Studies   No. Strains   Prevalence (%) (95% CI)
  ------- ---------- ------------------------------------------------- ------------- ------------- -------------------------
  hVISA   SCC*mec*                                                     16            685           
                     SCC*mec* I                                                                    2.12 (0.70--4.30)
                     SCC*mec* II                                                                   48.16 (32.82--63.68)
                     SCC*mec* III                                                                  17.99 (7.69--31.42)
                     SCC*mec* IV                                                                   18.07 (7.50--31.98)
          MLST                                                         10            454           
                     ST239                                                                         58.62 (22.98--89.73)
                     ST5                                                                           14.45 (4.59--28.53)
                     ST72                                                                          3.28 (0.98--6.88)
                     ST59                                                                          1.64 (0.28--4.10)
                     ST900                                                                         0.95 (0.13--2.49)
                     Others (ST1, ST247, ST228, ST398, ST45, ST1301)                               9.51 (0.48--27.95)
  VISA    SCC*mec*                                                     9             97            
                     SCC*mec* I                                                                    11.79 (0.01--40.76)
                     SCC*mec* II                                                                   37.74 (10.01--70.94)
                     SCC*mec* III                                                                  32.72 (3.35--73.85)
                     SCC*mec* IV                                                                   10.08 (1.77--24.05)
          MLST                                                         6             62            
                     ST239                                                                         27.05 (2.34--65.22)
                     ST5                                                                           22.77 (4.66--49.26)
                     Others (ST59, ST72, ST228, ST8)                                               42.44 (10.44--78.65)

CI, confidence interval

^a^References: \[[@pone.0136082.ref021], [@pone.0136082.ref026], [@pone.0136082.ref028], [@pone.0136082.ref029], [@pone.0136082.ref033], [@pone.0136082.ref044], [@pone.0136082.ref046], [@pone.0136082.ref052], [@pone.0136082.ref055], [@pone.0136082.ref059], [@pone.0136082.ref065], [@pone.0136082.ref070]--[@pone.0136082.ref072], [@pone.0136082.ref074], [@pone.0136082.ref076], [@pone.0136082.ref083], [@pone.0136082.ref084], [@pone.0136082.ref086], [@pone.0136082.ref092], [@pone.0136082.ref105]\]

Discussion {#sec018}
==========

The infections caused by MRSA are problematic because they entail high mortality and only limited antimicrobial drugs are available for their treatment \[[@pone.0136082.ref109]\]. Vancomycin has generally been the first drug of choice for the treatment of MRSA infections \[[@pone.0136082.ref110]\]. However, studies have reported that the treatment failure rate for vancomycin is increasing. Takesue et al. studied 128 strains of MRSA causing bacteremia and reported that the efficacy of vancomycin in patients infected with strains with a vancomycin MIC of ≤ 1 μg/ml was 78.8%, whereas it was only 30.0% for patients infected with strains with an MIC of 2 μg/ml \[[@pone.0136082.ref111]\]. Moore et al. also investigated MRSA bacteremia, and defined treatment failure as a composite of mortality, microbiological failure, and/or the recurrence of infection. The treatment failure rate was 31% in patients infected with 118 MRSA strains with vancomycin MIC \> 1 μg/ml \[[@pone.0136082.ref112]\]. Casapao et al. defined treatment failure as bacteremia for \> 7 days or death attributable to MRSA, and observed 64.4% treatment failure in 266 patients with MRSA endocarditis \[[@pone.0136082.ref044]\]. hVISA and VISA are thought to be among the primary causes of treatment failure. However, in 76 studies (including 99,042 strains) chosen for our analysis, the prevalence of hVISA was only 6.05%, and the prevalence of VISA was only 3.01% in 68,792 strains in 38 studies. Therefore, we speculate that the incidence of hVISA/VISA was underestimated, possibly because of the resistance mechanisms and biological characteristics of these strains. Unlike MRSA and vancomycin-resistant *S*. *aureus* (VRSA), the genetic backgrounds associated with hVISA/VISA remain unclear, and a molecular biological method to detect these strains is not yet available. The growth rates of hVISA/VISA are also slow \[[@pone.0136082.ref113], [@pone.0136082.ref114]\]; hence, conventional methods, such as the Kirby--Bauer and instrument-based methods, do not produce accurate results. The PAP-AUC method is considered the gold standard technique for detecting hVISA. However, this method is time-consuming, cumbersome, and unsuitable for clinical laboratories \[[@pone.0136082.ref069]\], so a significant number of strains may have been missed. Therefore, there is an urgent need for a convenient and effective method with which to detect these strains.

To analyze the trends in the prevalence of hVISA/VISA in recent years, we divided the study period into three periods: before 2006, 2006--2009, and 2010--2014. The first period used the initial resistance breakpoint (vancomycin MIC of 8--16 μg/ml) and the two later periods used the present resistance breakpoint (vancomycin MIC of 4--8 μg/ml). Our study suggests that the prevalence of hVISA/VISA has been increasing in recent years. We consider that the more frequent use of vancomycin for MRSA infections is responsible for this situation because the high prevalence of hVISA/VISA reflects the level of vancomycin use \[[@pone.0136082.ref115], [@pone.0136082.ref116]\]. The inappropriate management of drug-resistant strains has accelerated the spread of hVISA/VISA, and the change in the vancomycin-resistance breakpoint has also contributed to the increase in the prevalence rate.

Since the first reports of hVISA/VISA, the occurrence rates of these strains have varied throughout the world: the incidence of hVISA was 6.81% in Asia and 5.60% in Europe/America, and that of VISA was 3.42% and 2.75%, respectively. Current evidence supports the proposition that hVISA/VISA is more endemic in Asian countries than in Europe/America. Several factors may account for this situation. First, most countries in Europe and America are developed, with high public hygiene standards and scrupulous antimicrobial treatments \[[@pone.0136082.ref069], [@pone.0136082.ref101], [@pone.0136082.ref102]\]. Second, the control of nosocomial infections is more successful in European and American countries \[[@pone.0136082.ref041], [@pone.0136082.ref095]\]. Third, Asia is the most populous region of the world, which can create an environment amenable to microbial transmission. The pooled prevalence rate for hVISA in mainland China was 15.78% \[[@pone.0136082.ref058], [@pone.0136082.ref071], [@pone.0136082.ref083], [@pone.0136082.ref084]\], and in India, the pooled prevalence rates for of hVISA and VISA were 12.41% and 15.09%, respectively \[[@pone.0136082.ref040], [@pone.0136082.ref051], [@pone.0136082.ref052], [@pone.0136082.ref085], [@pone.0136082.ref099]\]. Fourth, because far more MRSA infections occur in Asian countries \[[@pone.0136082.ref117]\], vancomycin has been used more frequently for their treatment. Therefore, it is not surprising that hVISA and VISA are more common in Asia than elsewhere.

Previous studies have demonstrated that hVISA/VISA are prevalent among bacteremic specimens, and that these strains can persist in the bloodstream for a long time \[[@pone.0136082.ref019]\]. Our analysis confirms that hVISA is more common in blood-borne MRSAs, consistent with previous opinion. However, the prevalence of VISA was not obviously higher among isolates from blood culture samples than other samples. The reason for this is unclear, but this result suggests that not only blood culture samples but all clinical samples should be given attention.

The *mecA* gene, which is located within the SCC*mec* element, is the specific genetic mechanism of methicillin resistance \[[@pone.0136082.ref118]\]. Many epidemiological studies have demonstrated that community-associated MRSA (CA-MRSA) can be distinguished from hospital-acquired MRSA (HA-MRSA) by the type of the SCC*mec* element present. The most common SCC*mec* types in CA-MRSA strains are SCC*mec* IV and V, whereas SCC*mec* I, II, and III predominate in HA-MRSA strains \[[@pone.0136082.ref119]\]. The results of our pooled analysis show that SCC*mec* II and III were the most prevalent molecular types among the VISA strains. Previous studies have demonstrated limited vancomycin-resistance potential in SCC*mec* IV MRSA clones \[[@pone.0136082.ref120]\]. However, we found that the prevalence of SCC*mec* IV in hVISA was similar to that of SCC*mec* III. This phenomenon suggests that hVISA is not limited to typical "hospital" clones of *S*. *aureus*.

MLST is a powerful and highly discriminatory method for analyzing the population structures and epidemiology of *S*. *aureus* \[[@pone.0136082.ref121]\]. Our study demonstrates that ST239 and ST5 are the most epidemic genotypes of hVISA/VISA. ST239 and ST5 are two international HA-MRSA lineages prevalent in Asia, South America, and Eastern Europe \[[@pone.0136082.ref122], [@pone.0136082.ref123]\]. ST239 MRSA strains are typically resistant to many classes of antibiotics, including β-lactams, fluoroquinolones, aminoglycosides, and macrolide antibiotics. Our results strongly suggest that hVISA and VISA are highly prevalent among international epidemic MRSA strains. Moreover, the genetic backgrounds of these strains are complex, and many ST types are dispersed among hVISA/VISA isolates, including ST59, ST72, and ST900 \[[@pone.0136082.ref070], [@pone.0136082.ref072], [@pone.0136082.ref074]\].

The present study had several limitations. Genetic information was available in only 27% (25/91) of the studies we reviewed, which could have led to publication bias and influenced our results. There was also considerable heterogeneity between studies because they differed in various study variables, such as the patient populations examined, testing methodologies used, study durations, previous vancomycin therapy, and concomitant illnesses. These confounding factors could not be circumvented with subgroup analyses. As in previous meta-analyses in which unexplained heterogeneity was identified, we accommodated this condition by using REM, in which the effects underlying the results of different studies are assumed to be drawn from a normal distribution \[[@pone.0136082.ref124]\]. However, this heterogeneity could not be balanced out by REM alone, so that the stability of the final results must have been affected by the heterogeneity of the sample.

In summary, the results of our study suggest that the prevalence rates of hVISA/VISA have increased in recent years. Our data also supports the view that hVISA/VISA are more prevalent in Asian countries than in Europe/America. Our study confirms that hVISA strains are more common in blood-borne MRSA than in other MRSA. Finally, the most epidemic genotypes of hVISA/VISA are SCC*mec* II and SCC*mec* III on SCC*mec* typing, and ST239 and ST5 on MLST typing, which are predominant among the HA-MRSA strains. However, the incidence of hVISA/VISA is grossly underestimated. Therefore, the detection of hVISA/VISA must be strengthened, especially in samples from patients with bacteremic HA-MRSA infections, and the use of vancomycin and nosocomial infections must be urgently and strictly controlled, particularly in Asian hospitals.
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